Literature DB >> 11819593

Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital.

Pasiri Sithinamsuwan, Teerha Piratvisuth, Wiwatana Tanomkiat, Nualta Apakupakul, Surat Tongyoo.   

Abstract

AIM:To determine the clinical presentations, survival and prognostic factors of hepatocellular carcinoma (HCC) in Southern Thailand.
METHODS: Retrospective analysis was performed on the 336 hepatocellular carcinoma patients treated at Songklanagarind hospital between 1 January 1991 and 31 January 1999.
RESULTS: Of these 336 patients, 276 were males and 60 were females. The mean age was 54.4 years. The common symptoms and signs were abdominal pain and hepatomegaly. The most common presentation of tumor was a dominant mass with daughter nodules. Portal vein involvement was found in 50% of total. Extrahepatic metastasis was found in 13%, and the lung was the most common site. There were 65.4% with evidence of cirrhosis and half of them were in Child's class B. HBsAg was positive in 72.6%. Regarding a(c)Okuda's tumor staging, 15%, 61% and 24% were stage I, II and III, respectively. Overall median survival was 2.1 months (11.5 2.6 and 0.7 months for stage I, II and III respectively). Treatments of HCC improved patient survival (5.5 months vs 1.6 months for untreated patients). Most common causes of death were hepatic failure. Using multivariate analysis, the prognostic factors identified were tumor staging, alpha-fetoprotein level above 10000&mgr;gcenter dotL(-1), extrahepatic metastasis, portal vein thrombosis and treatment.
CONCLUSION: HCC in Thailand is a fatal disease with poor outcome due to late presentation and high prevalence of liver cirrhosis. Early detection and proper management may improve outcome.

Entities:  

Year:  2000        PMID: 11819593      PMCID: PMC4688747          DOI: 10.3748/wjg.v6.i3.339

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 2.  Primary liver cancer. Quadrennial review lecture.

Authors:  K Okuda
Journal:  Dig Dis Sci       Date:  1986-09       Impact factor: 3.199

3.  Factors affecting the prognosis of primary liver carcinoma.

Authors:  F M Sutton; N C Russell; V F Guinee; E Alpert
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

Review 4.  The clinical manifestations and natural history of hepatocellular carcinoma.

Authors:  C Kassianides; M C Kew
Journal:  Gastroenterol Clin North Am       Date:  1987-12       Impact factor: 3.806

Review 5.  Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients.

Authors:  F Nomura; K Ohnishi; Y Tanabe
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

6.  Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients.

Authors:  M Ebara; R Hatano; H Fukuda; M Yoshikawa; N Sugiura; H Saisho
Journal:  Hepatogastroenterology       Date:  1998-08

7.  Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients.

Authors:  X Calvet; J Bruix; P Ginés; C Bru; M Solé; R Vilana; J Rodés
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

8.  Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

Authors:  J Bruix; J M Llovet; A Castells; X Montañá; C Brú; M C Ayuso; R Vilana; J Rodés
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

Review 9.  Screening studies and markers.

Authors:  D B Jones; D J Koorey
Journal:  Gastroenterol Clin North Am       Date:  1987-12       Impact factor: 3.806

10.  Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.

Authors:  A Castells; J Bruix; C Brú; C Ayuso; M Roca; L Boix; R Vilana; J Rodés
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

View more
  21 in total

1.  Percutaneous transsplenic embolization of esophageal and gastrio-fundal varices in 18 patients.

Authors:  G Q Gong; X L Wang; J H Wang; Z P Yan; J M Cheng; S Qian; Y Chen
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

2.  Preparation and characterization of polyclonal antibodies against ARL-1 protein.

Authors:  Jun-Fei Jin; Liu-Di Yuan; Li Liu; Zhu-Jiang Zhao; Wei Xie
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Construction and expression of recombined human AFP eukaryotic expression vector.

Authors:  Li-Wang Zhang; Jun Ren; Liang Zhang; Hong-Mei Zhang; Bin Jin; Bo-Rong Pan; Xiao-Ming Si; Yan-Jun Zhang; Zhong-Hua Wang; Yang-Lin Pan; Stephen M Festein
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 4.  Brain metastasis of hepatocellular carcinoma: A case report and review of the literature.

Authors:  Bilge Tunc; Levent Filik; Irsel Tezer-Filik; Burhan Sahin
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection.

Authors:  Saadettin Kilickap; Ayse Kars; Erhan Hamaloglu; Halis Simsek
Journal:  Med Oncol       Date:  2009-08-18       Impact factor: 3.064

6.  Gene expression profiles of hepatoma cell line HLE.

Authors:  Lian-Xin Liu; Zhi-Hua Liu; Hong-Chi Jiang; Wei-Hui Zhang; Shu-Yi Qi; Jie Hu; Xiu-Qin Wang; Min Wu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

7.  Role of preoperative selective portal vein embolization in two-step curative hepatectomy for hepatocellular carcinoma.

Authors:  Wu Ji; Jie-Shou Li; Ling-Tang Li; Wu-Hong Liu; Kuan-Sheng Ma; Xiang-Tian Wang; Zhen-Ping He; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas.

Authors:  Xiao-Ping Li; Zhen Chen; Zhi-Qiang Meng; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

9.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.

Authors:  Xiaoyong Fu; Lu Tan; Shuqin Liu; Honghai Li; Lei Chen; Jianmin Qin; Mengchao Wu; Hongyang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.